MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Bio-IT World
November 2005
Kevin Davies
A Win-Win Situation The inaugural Bridging Discovery and IT conference explored critical issues facing discovery, clinical, and IT teams struggling to communicate and collaborate in biopharma organizations. mark for My Articles similar articles
Bio-IT World
April 2007
Vicki Glaser
Software Solutions for Medicinal Chemistry Driven by advances in chemical synthesis, instrumentation, and high-throughput and high-content screening technology, medicinal chemistry's transition from an art to a science is benefiting from a wealth of new software products, spanning both bio- and cheminformatics. mark for My Articles similar articles
Bio-IT World
April 15, 2003
Mark D. Uehling
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. mark for My Articles similar articles
Chemistry World
June 1, 2012
Derek Lowe
Peace, love and understanding You'd think that the chemists and biologists working in drug discovery would understand each other pretty well by now. You would be wrong about that. mark for My Articles similar articles
Bio-IT World
March 2006
Mike May
The Evolving Grid Computing System at J&J Johnson & Johnson is planning to double the size of its grid computing network and the number of applications that run on it by the end of this year, according to company executives. mark for My Articles similar articles
Bio-IT World
May 2006
Mike May
Drug Discovery As Easy As Pie A Johnson & Johnson pharmaceutical researcher has developed a software application that takes data from a compound, compares it to best-case values, and codes related measurements with color to assess the compound's potential as a drug. mark for My Articles similar articles
BusinessWeek
April 17, 2006
Amy Barrett
J&J: Reinventing How It Invents Johnson & Johnson bets on a new push for product development as a cure for its ailing stock. mark for My Articles similar articles
BusinessWeek
October 10, 2005
J&J: How A Dealmaker Nurtures Newcomers Johnson & Johnson has a good track record for retaining employees after a takeover. The company's broadly decentralized structure, which gives managers great leeway - no small thing for execs used to running their own shows. mark for My Articles similar articles
BusinessWeek
September 30, 2009
Arlene Weintraub
J&J Tries to Buy Itself a Pipeline It's snapping up biotechs, spearheading innovative alliances, and reshuffling R&D. mark for My Articles similar articles
The Motley Fool
November 26, 2007
Brian Orelli
Johnson & Johnson Reorganizes -- Who Wins? Johnson & Johnson announces the second phase of its reorganization plan. While it may take years to see whether the measures will help J&J, some other companies could benefit far more quickly. mark for My Articles similar articles
The Motley Fool
October 12, 2007
Billy Fisher
Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward. mark for My Articles similar articles
The Motley Fool
January 24, 2006
Stephen D. Simpson
Shake a Leg, J&J! J&J isn't a perfect story, but investors who buy today and hold for a while will be happy they did. mark for My Articles similar articles
BusinessWeek
June 18, 2007
Arlene Weintraub
J&J's New Baby As other divisions stumble, Johnson & Johnson's consumer products - bolstered by a $16.6 billion addition - provide a security blanket. mark for My Articles similar articles
The Motley Fool
November 22, 2006
Brian Lawler
Dueling Fools: Johnson & Johnson Bear Rebuttal The bottom line is that investors are putting their faith in the ability of J&J's management to acquire its way to renewing top-line growth in the coming years. mark for My Articles similar articles
The Motley Fool
November 22, 2006
Steven Mallas
Dueling Fools: Johnson & Johnson Bull There are many ways to expose one's portfolio to the health-care industry. But J&J offers the best upside potential at relatively little risk. mark for My Articles similar articles
BusinessWeek
June 18, 2007
Arlene Weintraub
Johnson & Johnson's Next Baby? J&J could use an infusion of new drugs and devices from an acquisition such as Boston Scientific. mark for My Articles similar articles
The Motley Fool
January 12, 2006
Stephen D. Simpson
The Guidant Auction Continues Johnson & Johnson hopes to save the deal with a last-minute raise of its offer. Although Boston Scientific's offer is $4 per share higher, that doesn't necessarily make it the best value. Investors, take note. mark for My Articles similar articles
The Motley Fool
November 15, 2005
Stephen D. Simpson
Guidant, J&J Kiss and Make Up The two companies hammered out a revised merger agreement that continues J&J's buyout of Guidant, but at a lower price. So what does this mean for the med-tech space, assuming that this deal actually goes through? Investors, take note. mark for My Articles similar articles
The Motley Fool
September 17, 2010
James Early
Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care. mark for My Articles similar articles
BusinessWeek
December 20, 2004
Amy Barrett
J&J: Don't Stop Dealmaking Now For years, health-care giant Johnson & Johnson has held on-again, off-again acquisition talks with medical-device maker Guidant Corp. But now, patent expirations and a thin pipeline mean the giant needs more than just Guidant. mark for My Articles similar articles
BusinessWeek
January 30, 2006
Robert Barker
Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber. mark for My Articles similar articles
BusinessWeek
April 23, 2007
Arlene Weintraub
Under The Weather At J&J Johnson & Johnson's three big products have seen setbacks, with little in sight to replace them. mark for My Articles similar articles
The Motley Fool
May 2, 2011
Anupama Pattanaik
J&J Attempts to Create Major "Synthes"-is Johnson & Johnson will acquire the medical device maker for $21.3 billion. mark for My Articles similar articles
Bio-IT World
November 2006
Kevin Davies
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights. mark for My Articles similar articles
Bio-IT World
February 2006
John Russell
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. mark for My Articles similar articles
The Motley Fool
August 24, 2010
Matt Koppenheffer
How Much Is Johnson & Johnson Worth? Is Johnson & Johnson's stock on sale? mark for My Articles similar articles
The Motley Fool
May 20, 2011
Andrea Kalvesmaki
Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings. mark for My Articles similar articles
The Motley Fool
November 3, 2005
Stephen D. Simpson
The At-Odds Couple Johnson & Johnson seems to want out, but Guidant looks willing to grab the shotgun to see that this union is completed. Investors, should the deal fall through, look for J&J to continue shopping and don't be surprised if Guidant attracts attention from Abbott Labs or Boston Scientific. mark for My Articles similar articles
The Motley Fool
April 13, 2006
Doug Short
A Foolish Baby Shower: Johnson & Johnson If you're an advocate of these two rules -- "It's never too early to start investing" and "Invest in what you know" -- then here is an ideal pick for baby's first stock. mark for My Articles similar articles
The Motley Fool
July 28, 2011
Melly Alazraki
J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet. mark for My Articles similar articles
Fast Company
March 2014
Adam Bluestein
Will Johnson & Johnson's New Innovation Centers Point The Way Toward Its Future? To visit the southeastern quadrant of Cambridge, Massachusetts, these days is to witness the rise of a new kind of city -- a glassy, gleaming pharmopolis dedicated to the discovery, development, and marketing of drugs. mark for My Articles similar articles
The Motley Fool
November 22, 2006
Brian Lawler
Dueling Fools: Johnson & Johnson Bear J&J's dividend does provide investors with some degree of income, but a CD does, too -- without a health-care stock's risks. mark for My Articles similar articles
The Motley Fool
July 26, 2005
Rich Smith
J&J: One Pricey Stock This giant of the health-care world reported its second quarter 2005 earnings last week but, by all appearances, failed to impress Wall Street. Johnson & Johnson's become very big, very pricey. mark for My Articles similar articles
The Motley Fool
December 31, 2007
Brian Orelli
Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008. mark for My Articles similar articles
The Motley Fool
March 24, 2011
Anand Chokkavelu
Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund." mark for My Articles similar articles
The Motley Fool
October 12, 2007
Ryan Fuhrmann
Dueling Fools: Johnson & Johnson Bull The bullish opinion on J&J is that the company is handling current difficulties well, and the low stock price makes for a bargain for investors. mark for My Articles similar articles
The Motley Fool
November 22, 2006
Steven Mallas
Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock. mark for My Articles similar articles
The Motley Fool
April 13, 2004
Alyce Lomax
J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter. mark for My Articles similar articles
Chemistry World
August 22, 2013
Phillip Broadwith
J&J buys Aragon's prostate cancer arm Hormonally-driven cancer drug discovery specialist Aragon Pharmaceuticals has been bought by Johnson & Johnson. mark for My Articles similar articles
The Motley Fool
October 7, 2010
Anand Chokkavelu
How Johnson & Johnson Really Makes Money Hint: It's not Tylenol. mark for My Articles similar articles
The Motley Fool
January 13, 2006
Stephen D. Simpson
Once More With Guidant In the ongoing game of tit-for-tat, Boston Scientific ups its bid for Guidant. This battle will ultimately be decided by the 800-pound gorilla that is J&J. Investors, take note. mark for My Articles similar articles
The Motley Fool
October 26, 2011
A Brief History of Johnson & Johnson's Returns J&J shares are much more reasonably valued today than they were ten years ago; shareholders are unlikely to experience the same going forward. mark for My Articles similar articles
BusinessWeek
April 17, 2006
Amy Barrett
Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created. mark for My Articles similar articles
The Motley Fool
January 20, 2004
Alyce Lomax
Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings. mark for My Articles similar articles
Chemistry World
October 1, 2014
Phillip Broadwith
J&J to buy antiviral specialist Alios Johnson and Johnson has agreed to buy antiviral specialist Alios BioPharma for $1.75 billion mark for My Articles similar articles
The Motley Fool
November 29, 2007
Anders Bylund
Mano a Mano Over Johnson & Johnson A look back at the past year at Johnson & Johnson. mark for My Articles similar articles
The Motley Fool
January 28, 2011
Anand Chokkavelu
10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo. mark for My Articles similar articles
The Motley Fool
June 26, 2006
Stephen D. Simpson
J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note. mark for My Articles similar articles
The Motley Fool
January 26, 2005
Rich Smith
J&J: Dialing for Dollars It pays to be big in a weak dollar world. Just ask Johnson & Johnson. Still, in the year to come, investors will want to keep one eye on J&J's operational performance, and the other on the U.S. Dollar's exchange rates against foreign currencies. mark for My Articles similar articles
The Motley Fool
February 24, 2004
Alyce Lomax
J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain? mark for My Articles similar articles